Role of the renin-angiotensin-aldosterone and kallikrein-kinin systems in the control of fluid and electrolyte metabolism, renal function, and arterial blood pressure.
The long-term effects of angiotensin I converting enzyme (kininase II) inhibition with Captopril on fluid and electrolyte metabolism, aldosterone secretion, renal function, and arterial pressure were evaluated in conscious sodium deficient dogs. Plasma aldosterone concentration (PAC), plasma renin activity (PRA), urinary sodium excretion (UNaV), arterial pressure (AP), renal blood flow (RBF), glomerular filtration rate (GFR), blood kinin concentration (BK), urinary kinin excretion (UK), and urinary kallikrein activity (UKA) were determined during long-term inhibition of angiotensin I converting enzyme (kininase II). In response to Captopril administration (20 mg/kg/day) PAC decreased from 38.9 +/- 6.7 to 14.3 +/- 2.3 ng/dl, PRA increased from 3.58 +/- 0.53 to 13.7 +/- 1.6 ng/ml/hr, UNaV increased from 0.65 +/- 0.27 to 6.4 +/- 1.2 mEq/day, AP decreased from 102 +/- 3 to 65 +/- 2 mmHg, RBF increased from 136 +/- 7 to 156 +/- 8 ml/min, GFR decreased from 65 +/- 8 to 36 +/- 7 ml/min, BK increased from 0.17 +/- 0.02 to 0.41 +/- 0.04 ng/ml, UK increased from 7.2 +/- 1.5 to 31.4 +/- 3.2 micrograms/day, and UKA decreased from 23.6 +/- 3.1 to 5.3 +/- 1.2 E.U./day. Aldosterone infusion in sodium deficient dogs maintained on Captopril failed to alter urinary sodium excretion, renal function, or arterial blood pressure. However, angiotensin II infusion (3 ng/kg/min) restored aldosterone secretion, renal function, and arterial blood pressure within three days to levels observed in untreated sodium deficient dogs. The marked alterations in renal function and urinary sodium excretion during angiotensin II infusion indicate that angiotensin II is several times more potent than aldosterone in the long-term control of sodium excretion. Also, our studies demonstrated that the long-term hypotensive and natriuretic actions of inhibitors of angiotensin I converting enzyme (kininase II) are mediated by inhibition of angiotensin II formation.
D000450:Aldosterone / Q000097:blood; D000804:Angiotensin II / Q000037:antagonists & inhibitors; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000494:pharmacology; D004285:Dogs; D007610:Kallikreins / Q000378:metabolism*; D007668:Kidney / Q000502:physiology*; D007705:Kinins / Q000378:metabolism* / Q000652:urine; D011433:Propranolol / Q000494:pharmacology; D012084:Renin-Angiotensin System / Q000187:drug effects; D012964:Sodium / Q000652:urine; D014882:Water-Electrolyte Balance
D007705:Kinins; D000804:Angiotensin II; D000450:Aldosterone; D002216:Captopril; D012964:Sodium; D011433:Propranolol; D007610:Kallikreins